
|Articles|December 4, 2007
Open letter from Genentech
Click here to read Genentech's open letter to ophthalmologists, outlining its reason for imposing restrictions on the use of Avastin.
Advertisement
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times Europe
1
IGS 2026: The expanding role of artificial intelligence in ophthalmology
2
Study finds artificial tear viscosity and shear-thinning behavior vary by formulation
3
Broadening horizons: Expanding your surgical portfolio with SMILE pro for Hyperopia
4
IGS 2026: Clinical pearls for detecting pre-perimetric glaucoma
5




























